The National Institutes of Health (NIH) in the United States is currently in the midst of phase III trials for a vaccine against HSV-2, called<unk> ac. The vaccine has only been shown to be effective for women who have never been exposed to HSV-1. Overall, the vaccine is approximately 48% effective in preventing HSV-2 seropositivity and about 78% effective in preventing symptomatic HSV-2. During initial trials, the vaccine did not exhibit any evidence of the prevention of HSV-2 in males.  Additionally, the vaccine only reduced the acquisition of HSV-2 and symptoms due to newly acquired HSV-2 among women who did not have HSV-2 infection at the time they got the vaccine.  Because about 20% of people in the United States have HSV-2 infection, this further reduces the population for whom this vaccine might be appropriate.
Herpes simplex primary prevention
Impetigo primary prevention
Contact Dermatitis primary prevention
Onychomycosis primary prevention
Onychomycosis medical therapy
Onychomycosis secondary prevention
Herpes zoster primary prevention
Dermatophytosis primary prevention